HEPSANET score for treatment eligibility

Our paper on determining treatment eligibility using HEPSANET cohort data has been published in the Lancet Gastroenterology and Hepatology. Using the EASL 2017 guidelines as a reference standard, we found that the use of platelets, ALT and AST could identify most patients who need treatment, without the need for expensive diagnostic tests such as transient elastography, liver biopsy or HBV DNA quantification.

This score could be applied in rural and remote settings where there is limited access to diagnostic tests.